ABSTRACT Oncology drug development continues to have a high attrition rate despite major advances in therapeutic modalities such as antibody‐drug conjugates, bispecific antibodies, cell therapies, and cancer vaccines. Critical development decisions are often made under substantial uncertainty, creating a need for quant...
Benjamin Wu, Kenta Yoshida, P. Chanu et al.· Clinical and Translational S...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.